Abstract: Indole-carboxylic acid compounds of the formula: ##STR1## wherein R.sub.1 is lower alkyl or alkoxy radical or halogen;R.sub.2 is halogen; lower alkyl or alkoxy radical; orR.sub.1 and R.sub.2 can together also form an alkylene bridge containing 3 to 5 carbon atoms, which can optionally contain one or more double bonds; and, but less preferably, when R.sub.1 is a lower alkyl or alkoxy radical, R.sub.2 can also be a hydrogen atom, and physiologically compatible salts and esters thereof,Are outstandingly effective as blood sugar-lowering agents.

Abstract: Coated tablets are prepared by applying to a core of active material, at least one layer of a coating composition made up of a film forming aqueous synthetic resin dispersion and from 2-50% by weight of a water or alkaline soluble material and thereafter permitting the coating composition layer to dry. The resulting coated tablet has a core surrounded by a continuous porous matrix of synthetic resin formed from the aqueous dispersion which is insoluble in water and insoluble in the gastrointestinal tract. The pores of the continuous resin matrix are filled with a discontinuous particulate material which is water or alkaline soluble. The coated tablet initially is air and moisture tight.

Abstract: A blood sugar lowering composition comprising as the active material particulate glibenclamide having a surface area of about 3 to 10 m.sup.2 /g in admixture with a pharmacologically acceptable non-ionic wetting agent present in about 2 to 20 times the weight of the glibenclamide. The preferred wetting agent is polyoxyethylene stearate present in about 5 to 10 times the weight of the glibenclamide.

Abstract: Cycloalkano-quinolone derivatives having anti-microbial activity characterized by the formula: ##STR1## wherein one of R.sub.1 and R.sub.2 designates hydrogen, halogen, nitro, amino, hydroxyl, acylamino, acyloxy, alkoxy or aryloxy and the other taken together with R.sub.3 forms an alkylene bridge containing 2 to 6 carbon atoms, X is hydrogen, lower alkyl, which may be substituted by a member of the group consisting of halogen, hydroxyl, acyloxy, alkoxy, aryloxy, aralkyloxy, mercapto, alkylmercapto, arylmercapto, arylsulfonyl, and alkylsulfonyl, or X is unsubstituted alkenyl including alkadienyl, or alkynyl and Y is hydroxyl, amino or lower alkoxy, and the pharmaceutically acceptable salts thereof.

Abstract: .gamma.-Glutamyl-4-nitroanilide compounds of the formula ##STR1## wherein R is a .gamma.-glutamyl radical and X is an acid group, and salts of such compounds, are used to determine .gamma.-glutamyl-transpeptidase by contacting a sample suspected of containing .gamma.-glutamyltranspeptidase with said compound and glycylglycine and determining the liberation of the resulting p-nitro-aniline compound as a measure of the .gamma.-glutamyltranspeptidase activity initially present in the sample.

Abstract: Biologically active proteins are bound onto an insoluble carrier by reacting such protein in an aqueous phase with a carrier comprising an activated polysaccharide having a hydrophilic graft co-polmyer grafted thereinto.

Abstract: New cyclopenteno-quinolone derivatives of the formula ##STR1## wherein R is a saturated or unsaturated aliphatic hydrocarbyl, e.g., alkyl and alkenyl,X is hydrogen or alkyl, andY is halogen, azido, alkylthio, alkyl-sulfonyl, or nitrile or unsubstituted or substituted (e.g., alkyl mono or di-substituted) amino;And the pharmacologically compatible salts thereof; are outstandingly effective as bacteriostats in mammals.

Abstract: New cyclopenteno-quinolone derivatives of the formula ##STR1## wherein R is a saturated or unsaturated aliphatic hydrocarbyl, e.g., alkyl and alkenyl,X is hydrogen or alkyl, andY is halogen, azido, alkylthio, alkyl-sulfonyl, or nitrile or unsubstituted or substituted (e.g., alkyl mono or di-substituted) amino;And the pharmacologically compatible salts thereof; are outstandingly effective as bacteriostats in mammals.

Abstract: Pharmaceutical compositions comprisingA. at least one member of 5-(4-chloro-5-sulfamoyl-2-thenylaminophenyl)-tetrazole and the pharmacologically compatible salts thereof,B. 3-(3-oxo-7.alpha.-acetylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)-pr opionic acid-.gamma.-lactone, andC. a pharmaceutical diluent or carrierPossess outstanding activity for treating hydropic conditions and prevent undesirable increased excretion of potassium without at the same time impairing the desired excretion of water and sodium.

Abstract: New N-substituted 1-amino-3-phenoxy-propan-2-ol compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are, individually, hydrogen or, taken together, represent a sulfur linkage, an ethylene radical or a valency bond;B is straight or branched chain alkylene or hydroxyalkylene of from 2 to 5 carbon atoms; andR.sub.3 is hydrogen or alkyl of up to 3 carbon atoms;And the physiologically compatible salts thereof; possess valuable cardiac and circulatory activity.

Abstract: An analytical process for enzymatic determination of a substrate in biological fluids. The fluid sample is reacted first in the absence of the specific kinase but in the presence of an NADH -- regenerating enzymatic system with the reagents needed for the reaction sequence; then the enzymes are separated from the reaction solution, and thereafter the necessary enzymes are added to the filtrate and NADH consumption is measured.The method is very accurate, economical in requiring less enzymes and only one measurement is necessary.

Abstract: New biguanide compounds of the formula: ##STR1## wherein A is saturated or unsaturated cycloaliphatic hydrocarbyl, and the physiologically compatible salts thereof; display outstanding anti-diabetic effectiveness in the treatment of diabetes mellitus, without showing the typical side effects of biguanide treatment, viz., lactacidosis.

Abstract: N(6)-disubstituted adenosine compounds of the formula: ##STR1## wherein R.sub.1 is alkenyl, cycloalkenyl or cycloalkenyl-alkyl; andR.sub.2 is alkenyl, cycloalkenyl, straight or branched-chain alkyl, cycloalkyl, bicycloalkyl, alkyl-cycloalkyl, or alkyl-bicycloalkyl;And the pharmacologically compatible salts thereof; exhibit outstanding anti-lipolytic, anti-hyperlipaemic and anti-hypercholesterolaemic action.

Abstract: Protein in body fluids, e.g., urine, is detected by contacting a sample of the body fluid with a diagnostic agent comprising an absorbent carrier impregnated with a pH indicator of the octahalosulfophthalein group, a buffer, and at least one linear or branched chain polypropylene glycol immiscible with water; the resulting test papers are highly sensitive to protein without being subject to interfering effects by nitrogen-containing compounds.

Abstract: Cholesterol oxidase which oxidizes cholesterol with oxygen to give cholestenone and hydrogen peroxide, is prepared by culturing Nocardia erthropolis ATCC 17895, Nocardia erthropolis ATCC 4277, Nocardia formica ATCC 14811 or Proactinomyce erythropolis NCIB 9158 first on a peptone-containing mineral salt medium and thereafter on at least one sterol compound as the sole source of carbon, and then isolating the cholesterol oxidase formed from the cultured micro-organism, wherein said sterol compound is of the formula ##STR1## in which R.sub.1 and R.sub.2 are hydrogen or together represent a double bond,R.sub.3 and R.sub.4 are hydrogen or together represent a double bond, andR.sub.5 is hydrogen or alkyl containing up to 3 carbon atoms.

Abstract: The method of preparing adjuvant-free tablets from a tableting mass having a tendency to stick, comprising alternately in the same mold forming tablets from said tableting mass and from an adjuvant mass containing an easily tableted substance, a lubricant and a mold parting agent. The lubricant may be talc or sodium benzoate present in about 5 to 20% by weight, and the mold release agent may be stearic acid, a stearate, paraffin or a silicone oil in about 0.5 to 10% by weight. By this method tablets of pure fructose can be formed.

Abstract: Nitroimidazolyl-s-triazolo[4,3-b]pyridazines of the formula: ##STR1## wherein R is hydrogen or lower alkyl optionally substituted in the 2-position by hydroxyl or by lower acyloxy or lower alkoxy;A is hydrogen, halogen, azido, cyano; lower alkyl alkoxy, alkylthio, alkylsulfonyl, carboxyl; lower alkoxycarbonyl, lower alkoxycarbonimidoyl; or hydrazino, carbamoyl, amidino or a carboximidohydrazide group optionally substituted by one or two lower acyl, alkyl or cycloalkyl radicals; orA is a radical of the formula: ##STR2## wherein R.sub.1 and R.sub.2 are, individually, hydrogen or a number of organic radicals or, taken together, can be an alkylene bridge; andR.sub.3 is hydrogen or lower alkyl; or, together with R.sub.2, R.sub.3 can form an alkylene bridge;n is 0 or 1;And the pharmaceutically compatible thereof, possess high in vivo effectiveness as antimicrobials.

Abstract: New N-substituted 1-amino-3-phenoxy-propan-2-ol compounds of the formula: ##EQU1## wherein R.sub.1 and R.sub.2 are, individually, hydrogen or, taken together, represent a sulfur linkage, an ethylene radical or a valency bond;B is straight or branched chain alkylene or hydroxyalkylene of from 2 to 5 carbon atoms; andR.sub.3 is hydrogen or alkyl of up to 3 carbon atoms;And the physiologically compatible salts thereof; possess valuable cardiac and circulatory activity.

Abstract: New 1-[3-naphth-1-yloxy)-propyl]-piperazine compounds of the formula: ##STR1## wherein X is hydrogen or methoxy;And the pharmacologically compatible salts thereof;Are outstandingly effective in lowering blood pressure and are thus useful as anti-hypertensive agents.

Abstract: New 1-[3-(naphth-1-yloxy)-2-hydroxypropyl]-piperazine compounds of the formula: ##STR1## and the pharmacologically compatible salts thereof are outstandingly effective in lowering blood pressure and are thus useful as anti-hypertensive agents.